Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Andrews

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
NPJ Primary Care Respiratory Medicine|June 9, 2025
Creating expert patients: outcomes from a national digital therapeutic approach for people with asthma in WalesSimon M Barry, Julian Forton, Gareth R Davies, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2008
Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylaminesDonald S Middleton, Mark Andrews, Paul Glossop, et al.
The American Journal of Cardiology|August 30, 2005
Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II)William N Brodine, Robert T Tung, John K Lee, et al.
Bioorganic & Medicinal Chemistry Letters|November 30, 2005
Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamineDonald S Middleton, Mark Andrews, Paul Glossop, et al.
Heart Rhythm|March 28, 2009
Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillatorsIwona Cygankiewicz, John Gillespie, Wojciech Zareba, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2008
Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylaminesDonald S Middleton, Mark Andrews, Paul Glossop, et al.
Early Intervention in Psychiatry|March 28, 2018
Implementing the access and waiting time standard for early intervention in psychosis in the United Kingdom: An evaluation of referrals and post-assessment outcomes over the first year of operationVidyah Adamson, Emma Barrass, Stephen McConville, et al.
Journal of Medicinal Chemistry|November 5, 2016
The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of PainSarah E Skerratt, Mark Andrews, Sharan K Bagal, et al.
Contemporary Clinical Trials|April 16, 2026
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trialArchana Gopalakrishnan, Alexander Light, Nikhil Mayor, et al.
Journal of Medicinal Chemistry|June 27, 2018
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of PainSharan K Bagal, Mark Andrews, Bruce M Bechle, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
NPJ Primary Care Respiratory Medicine|June 9, 2025
Creating expert patients: outcomes from a national digital therapeutic approach for people with asthma in WalesSimon M Barry, Julian Forton, Gareth R Davies, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2008
Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylaminesDonald S Middleton, Mark Andrews, Paul Glossop, et al.
The American Journal of Cardiology|August 30, 2005
Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II)William N Brodine, Robert T Tung, John K Lee, et al.
Bioorganic & Medicinal Chemistry Letters|November 30, 2005
Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamineDonald S Middleton, Mark Andrews, Paul Glossop, et al.
Heart Rhythm|March 28, 2009
Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillatorsIwona Cygankiewicz, John Gillespie, Wojciech Zareba, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2008
Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylaminesDonald S Middleton, Mark Andrews, Paul Glossop, et al.
Early Intervention in Psychiatry|March 28, 2018
Implementing the access and waiting time standard for early intervention in psychosis in the United Kingdom: An evaluation of referrals and post-assessment outcomes over the first year of operationVidyah Adamson, Emma Barrass, Stephen McConville, et al.
Journal of Medicinal Chemistry|November 5, 2016
The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of PainSarah E Skerratt, Mark Andrews, Sharan K Bagal, et al.
Contemporary Clinical Trials|April 16, 2026
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trialArchana Gopalakrishnan, Alexander Light, Nikhil Mayor, et al.
Journal of Medicinal Chemistry|June 27, 2018
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of PainSharan K Bagal, Mark Andrews, Bruce M Bechle, et al.
Pageof 7